{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:52:57Z","timestamp":1790103177106,"version":"4.0.1"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25\\u202FK12740"],"award-info":[{"award-number":["25\\u202FK12740"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ctrv.2025.102993","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T13:51:19Z","timestamp":1752587479000},"page":"102993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Palliative systemic therapy for locally advanced or metastatic salivary duct carcinoma: A comprehensive review"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6659-0997","authenticated-orcid":false,"given":"Masafumi","family":"Kanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiyo","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Takabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeharu","family":"Fujieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.102993_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693394","article-title":"HER2 positivity in histological subtypes of salivary gland carcinoma: A systematic review and meta-analysis","volume":"11","author":"Egebjerg","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/BF00301495","article-title":"A group of salivary gland tumors analogous to mammary duct carcinoma","volume":"192","author":"Kleinsasser","year":"1968","journal-title":"Arch Klin Exp Ohren Nasen Kehlkopfheilkd."},{"key":"10.1016\/j.ctrv.2025.102993_b0015","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.ctrv.2025.102993_b0020","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.30957","article-title":"Heterogeneous impact of smoking on major salivary gland cancer according to histopathological subtype: A case\u2010control study","volume":"124","author":"Sawabe","year":"2018","journal-title":"Cancer."},{"key":"10.1016\/j.ctrv.2025.102993_b0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1017\/S0022215100098807","article-title":"Salivary duct adenocarcinoma: A high grade malignancy","volume":"100","author":"Hui","year":"1986","journal-title":"J Laryngol Otol."},{"key":"10.1016\/j.ctrv.2025.102993_b0030","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/1097-0142(19930901)72:5<1503::AID-CNCR2820720503>3.0.CO;2-K","article-title":"Salivary duct carcinoma","volume":"72","author":"Delgado","year":"1993","journal-title":"Cancer."},{"key":"10.1016\/j.ctrv.2025.102993_b0035","doi-asserted-by":"crossref","unstructured":"Speight PM, Takata T. New tumour entities in the 4th edition of the World Health Organization Classification of Head and Neck tumours: Odontogenic and maxillofacial bone tumours. Virchows Arch. 2018;472:331\u20139. doi: 10.1007\/s00428-017-2182-3.","DOI":"10.1007\/s00428-017-2182-3"},{"key":"10.1016\/j.ctrv.2025.102993_b0040","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hed.23350","article-title":"Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database","volume":"36","author":"Jayaprakash","year":"2014","journal-title":"Head Neck."},{"key":"10.1016\/j.ctrv.2025.102993_b0045","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/hed.25194","article-title":"Salivary duct carcinoma: Prospective multicenter study of 61 cases of the R\u00e9seau d\u2019Expertise Fran\u00e7ais des Cancers ORL Rares","volume":"41","author":"Villepelet","year":"2019","journal-title":"Head Neck."},{"issue":"suppl 1","key":"10.1016\/j.ctrv.2025.102993_b0050","first-page":"E820","article-title":"Salivary duct carcinoma: Treatment, outcomes, and patterns of failure","volume":"38","author":"Johnston","year":"2016","journal-title":"Head Neck."},{"key":"10.1016\/j.ctrv.2025.102993_b0055","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hed.25035","article-title":"Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in the Netherlands","volume":"40","author":"Boon","year":"2018","journal-title":"Head Neck."},{"key":"10.1016\/j.ctrv.2025.102993_b0060","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cncy.22288","article-title":"Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment","volume":"128","author":"Nakaguro","year":"2020","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.ctrv.2025.102993_b0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10147-014-0674-6","article-title":"Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma","volume":"20","author":"Masubuchi","year":"2015","journal-title":"Int J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0070","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1634\/theoncologist.2012-0369","article-title":"Trastuzumab for the treatment of salivary duct carcinoma","volume":"18","author":"Limaye","year":"2013","journal-title":"Oncologist."},{"key":"10.1016\/j.ctrv.2025.102993_b0075","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1002\/hed.23383","article-title":"Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy","volume":"36","author":"Soper","year":"2014","journal-title":"Head Neck."},{"key":"10.1016\/j.ctrv.2025.102993_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102069","article-title":"Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review","volume":"89","author":"Uijen","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ctrv.2025.102993_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100602","article-title":"Salivary gland cancer: ESMO\u2013European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"7","author":"van Herpen","year":"2022","journal-title":"ESMO Open."},{"key":"10.1016\/j.ctrv.2025.102993_b0090","doi-asserted-by":"crossref","unstructured":"Colevas AD, Cmelak AJ, Pfister DG, Spencer S, Adkins D, Birkeland AC, et al. NCCN Guidelines\u00ae Insights: Head and Neck Cancers, Version 2.2025. J Natl Compr Canc Netw. 2025;23(2):2\u201311. doi: 10.6004\/jnccn.2025.0007.","DOI":"10.6004\/jnccn.2025.0007"},{"key":"10.1016\/j.ctrv.2025.102993_b0095","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of salivary gland malignancy: ASCO Guideline: ASCO Guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hed.20327","article-title":"Phase II trial of Taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group","volume":"28","author":"Gilbert","year":"2006","journal-title":"Head Neck."},{"key":"10.1016\/j.ctrv.2025.102993_b0105","doi-asserted-by":"crossref","first-page":"S1227","DOI":"10.1016\/j.annonc.2024.08.2275","article-title":"LBA36 A randomised phase II study to evaluate the efficacy and safety of androgen deprivation therapy (ADT) vs chemotherapy (CT) in patients with recurrent and\/or metastatic, androgen receptor (AR) expressing, salivary gland cancers","volume":"35","author":"Licitra","year":"2024","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0110","first-page":"701","article-title":"First Line androgen Deprivation Therapy vs. chemotherapy for Patients with androgen receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma-A Retrospective Study. Front","volume":"9","author":"Viscuse","year":"2019","journal-title":"Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0115","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3109\/00016489.2016.1170876","article-title":"Combination chemotherapy of carboplatin and paclitaxel for advanced\/metastatic salivary gland carcinoma patients: Differences in responses by different pathological diagnoses","volume":"136","author":"Nakano","year":"2016","journal-title":"Acta Oto-Laryngol."},{"key":"10.1016\/j.ctrv.2025.102993_b0120","doi-asserted-by":"crossref","first-page":"843","DOI":"10.21873\/invivo.11549","article-title":"Carboplatin and docetaxel in patients with salivary gland carcinoma: A retrospective study","volume":"33","author":"Okada","year":"2019","journal-title":"In Vivo."},{"key":"10.1016\/j.ctrv.2025.102993_b0125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12032-021-01581-z","article-title":"Docetaxel plus cisplatin in recurrent and\/or metastatic non-squamous-cell head and neck cancer: A multicenter phase II trial","volume":"38","author":"Imamura","year":"2021","journal-title":"Med Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0130","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4143\/crt.2021.1019","article-title":"A single-arm, prospective, Phase II study of cisplatin plus weekly docetaxel as first-line therapy in patients with metastatic or recurrent salivary gland cancer","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res Treat."},{"key":"10.1016\/j.ctrv.2025.102993_b0135","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cncr.24745","article-title":"A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: A trial of the NCIC Clinical Trials Group","volume":"116","author":"Laurie","year":"2010","journal-title":"Cancer."},{"key":"10.1016\/j.ctrv.2025.102993_b0140","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17843286.2016.1173940","article-title":"Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: A series of six patients","volume":"71","author":"De Block","year":"2016","journal-title":"Acta Clin Belg."},{"issue":"11","key":"10.1016\/j.ctrv.2025.102993_b0145","first-page":"111","article-title":"Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)\u2013positive advanced salivary duct carcinoma: A case report","volume":"2019","author":"Gibo","year":"2019","journal-title":"Mol Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0150","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.6004\/jnccn.2018.7056","article-title":"First-line treatment of widely metastatic BRAF -Mutated salivary duct carcinoma with combined BRAF and MEK inhibition","volume":"16","author":"Lin","year":"2018","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.ctrv.2025.102993_b0155","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1017\/S0022215108002314","article-title":"Biological therapy of salivary duct carcinoma","volume":"123","author":"Nashed","year":"2009","journal-title":"J Laryngol Otol."},{"key":"10.1016\/j.ctrv.2025.102993_b0160","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3892\/mco.2017.1226","article-title":"Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report","volume":"6","author":"Kawahara","year":"2017","journal-title":"Mol Clin Oncol."},{"issue":"175883592211195","key":"10.1016\/j.ctrv.2025.102993_b0165","article-title":"Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma","volume":"14","author":"Kawakita","year":"2022","journal-title":"Ther Adv Med Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0170","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0175","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hed.23940","article-title":"Clinical activity of androgen deprivation therapy in patients with metastatic\/relapsed androgen receptor-positive salivary gland cancers","volume":"38","author":"Locati","year":"2016","journal-title":"Head Neck."},{"key":"10.1016\/j.ctrv.2025.102993_b0180","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1200\/JCO.21.00468","article-title":"Abiraterone acetate in patients with castration-resistant, androgen receptor-expressing salivary gland cancer: A Phase II trial","volume":"39","author":"Locati","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0185","doi-asserted-by":"crossref","unstructured":"Honma Y, Monden N, Yamazaki K, Kano S, Satake H, Kadowaki S, et al. Apalutamide and goserelin for androgen receptor\u2013positive salivary gland carcinoma: A Phase II nonrandomized clinical trial, YATAGARASU. Clin Cancer Res. Published online July 23, 2024. 2024;30:OF1-OF12. doi: 10.1158\/1078-0432.CCR-24-0455.","DOI":"10.1158\/1078-0432.c.7403487"},{"key":"10.1016\/j.ctrv.2025.102993_b0190","article-title":"Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers","volume":"37(15_suppl):6020","author":"Ho","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0195","article-title":"Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy","volume":"41(16_suppl):6093","author":"Okano","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0200","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1200\/JCO.2010.32.8351","article-title":"Androgen receptor-positive salivary duct carcinoma: A disease entity with promising new treatment options","volume":"29","author":"Jaspers","year":"2011","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0205","doi-asserted-by":"crossref","first-page":"ix344","DOI":"10.1016\/S0923-7534(20)33608-5","article-title":"Anti-androgen Therapy for the Patients with Recurrent and\/or Metastatic Salivary Duct Carcinoma Expressing androgen Receptors: A Retrospective Study","volume":"23","author":"Yajima","year":"2012","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0210","article-title":"Darolutamide plus goserelin for androgen receptor-positive salivary gland cancers: Results of phase 2 study (DISCOVARY)","volume":"43(16_suppl):6007","author":"Okano","year":"2025","journal-title":"J Clin Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2025.102993_b0215","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e18091","article-title":"BTCRC-HN17-111, A phase 2 trial of ADT (goserelin) in combination with pembrolizumab for patients with advanced salivary gland tumors expressing androgen receptor (AR)","volume":"40","author":"Patel","year":"2022","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0220","first-page":"2587","article-title":"The role of trastuzumab in the management of salivary ductal carcinomas","volume":"33","author":"Perissinotti","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ctrv.2025.102993_b0225","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/cncr.33968","article-title":"Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified","volume":"128","author":"Sousa","year":"2022","journal-title":"Cancer."},{"key":"10.1016\/j.ctrv.2025.102993_b0230","article-title":"Abstract CT137: Phase II study of trastuzumab and docetaxel therapy in patients with HER2-positive recurrent and\/or metastatic salivary gland carcinoma","volume":"79(13_Suppl):CT137","author":"Kinoshita","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctrv.2025.102993_b0235","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0240","doi-asserted-by":"crossref","unstructured":"Lee J, Park S, Jung HA, Lee SH, Seo S, Kim SB, et al. A phase 2 multicenter study of docetaxel\u2010PM and trastuzumab\u2010pkrb combination therapy in recurrent or metastatic salivary gland carcinomas. Published online May 28. Cancer. 2023;129:2966\u201374. doi: 10.1002\/cncr.34892.","DOI":"10.1002\/cncr.34892"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102993_b0245","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.02636","article-title":"MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2\u2013Altered Advanced Solid Tumors","volume":"42","author":"Sweeney","year":"2023","journal-title":"J Clin Oncol."},{"issue":"12","key":"10.1016\/j.ctrv.2025.102993_b0250","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0255","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial","volume":"37(15_suppl):6001","author":"Li","year":"2019","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.ctrv.2025.102993_b0260","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0265","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/jjco\/hyad181","article-title":"Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2\u2013expressing salivary gland carcinoma: A pooled analysis of two phase I studies","volume":"54","author":"Takahashi","year":"2024","journal-title":"Jpn J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0270","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.3390\/ijms25042366","article-title":"NTRK therapy among different types of cancers, review and future perspectives","volume":"25","author":"Theik","year":"2024","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.ctrv.2025.102993_b0275","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ctrv.2025.102993_b0280","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0285","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0290","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41698-022-00324-1","article-title":"Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling","volume":"6","author":"Kohsaka","year":"2022","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106751","article-title":"Differential expression of TRKB tyrosine kinase in the two histological types of parotid salivary duct carcinoma with cancer aggressiveness","volume":"151","author":"Moriwaki","year":"2024","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2020.151673","article-title":"The significance of tyrosine kinase receptor B and brain-derived neurotrophic factor expression in salivary duct carcinoma","volume":"50","author":"Kondo","year":"2021","journal-title":"Ann Diagn Pathol."},{"key":"10.1016\/j.ctrv.2025.102993_b0305","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/annonc\/mdx399","article-title":"Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies","volume":"28","author":"Ross","year":"2017","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0310","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/ijc.34972","article-title":"Comprehensive genomic profiling of salivary gland carcinoma: Analysis of the Center for Cancer Genomics and Advanced Therapeutics database in Japan","volume":"155","author":"Iwaki","year":"2024","journal-title":"Int J Cancer."},{"key":"10.1016\/j.ctrv.2025.102993_b0315","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ctrv.2025.102993_b0320","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.6004\/jnccn.2018.7056","article-title":"First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition","volume":"16","author":"Lin","year":"2018","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.ctrv.2025.102993_b0325","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4103\/CRST.CRST_258_20","article-title":"Molecular tumor board: Case 4 Salivary Gland Cancer: Novel therapeutic options as a result of comprehensive molecular profiling","volume":"3","author":"Kapoor","year":"2020","journal-title":"Cancer Res Stat Treat."},{"key":"10.1016\/j.ctrv.2025.102993_b0330","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","article-title":"Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer","volume":"22","author":"Dalin","year":"2016","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ctrv.2025.102993_b0335","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","author":"Network","year":"2015","journal-title":"Nature."},{"key":"10.1016\/j.ctrv.2025.102993_b0340","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1002\/cncr.33036","article-title":"Tipifarnib in recurrent, metastatic HRAS\u2010mutant salivary gland cancer","volume":"126","author":"Hanna","year":"2020","journal-title":"Cancer."},{"key":"10.1016\/j.ctrv.2025.102993_b0345","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2016.09.022","article-title":"A phase II study of sorafenib in recurrent and\/or metastatic salivary gland carcinomas: Translational analyses and clinical impact","volume":"69","author":"Locati","year":"2016","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.ctrv.2025.102993_b0350","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0355","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.30537","article-title":"Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01)","volume":"123","author":"Kim","year":"2017","journal-title":"Cancer."},{"key":"10.1016\/j.ctrv.2025.102993_b0360","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/hed.25891","article-title":"Phase II trial with axitinib in recurrent and\/or metastatic salivary gland cancers of the upper aerodigestive tract","volume":"41","author":"Locati","year":"2019","journal-title":"Head Neck."},{"key":"10.1016\/j.ctrv.2025.102993_b0365","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1158\/1078-0432.CCR-15-2568","article-title":"Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ctrv.2025.102993_b0370","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): A phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0375","article-title":"Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial","volume":"39(15_suppl):3079","author":"Subbiah","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0380","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2007.11.8612","article-title":"Phase II Study of Lapatinib in Recurrent or Metastatic epidermal growth factor receptor and\/or erbB2 Expressing Adenoid Cystic Carcinoma and Non-Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands","volume":"25","author":"Agulnik","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0385","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.oraloncology.2008.07.010","article-title":"Cetuximab in recurrent and\/or metastatic salivary gland carcinomas: A phase II study","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0390","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hed.23647","article-title":"Phase II study of gefitinib in patients with advanced salivary gland cancers","volume":"37","author":"Jakob","year":"2015","journal-title":"Head Neck."},{"key":"10.1016\/j.ctrv.2025.102993_b0395","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/bjc.2013.468","article-title":"Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: A phase II trial","volume":"109","author":"Hitre","year":"2013","journal-title":"Br J Cancer."},{"key":"10.1016\/j.ctrv.2025.102993_b0400","doi-asserted-by":"crossref","first-page":"979","DOI":"10.21873\/invivo.12790","article-title":"Retrospective study of cisplatin\/carboplatin, 5-fluorouracil plus cetuximab (EXTREME) for advanced-stage salivary gland cancer","volume":"36","author":"Nakano","year":"2022","journal-title":"In Vivo."},{"key":"10.1016\/j.ctrv.2025.102993_b0405","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000534516","article-title":"Efficacy of cetuximab combined with paclitaxel in patients with recurrent salivary gland carcinoma: A retrospective observational study","volume":"86","author":"Sato","year":"2024","journal-title":"ORL J Otorhinolaryngol Relat Spec."},{"key":"10.1016\/j.ctrv.2025.102993_b0410","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/jop.12394","article-title":"Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer","volume":"45","author":"Ach","year":"2016","journal-title":"J Oral Pathol Med."},{"key":"10.1016\/j.ctrv.2025.102993_b0415","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): An international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0420","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/1078-0432.CCR-12-1842","article-title":"Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment","volume":"19","author":"Nardi","year":"2013","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ctrv.2025.102993_b0425","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1002\/hed.23429","article-title":"Human epidermal receptor 2-amplified salivary duct carcinoma: Regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment","volume":"36","author":"Falchook","year":"2014","journal-title":"Head Neck."},{"key":"10.1016\/j.ctrv.2025.102993_b0430","doi-asserted-by":"crossref","first-page":"e727","DOI":"10.1200\/JCO.2011.36.2095","article-title":"Salivary duct carcinoma: Targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with Temsirolimus","volume":"29","author":"Piha-Paul","year":"2011","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0435","doi-asserted-by":"crossref","first-page":"16988","DOI":"10.1038\/s41598-020-73965-6","article-title":"Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma","volume":"10","author":"Niwa","year":"2020","journal-title":"Sci Rep."},{"key":"10.1016\/j.ctrv.2025.102993_b0440","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1038\/s41591-023-02518-x","article-title":"Nivolumab plus ipilimumab in advanced salivary gland cancer: A phase 2 trial","volume":"29","author":"Vos","year":"2023","journal-title":"Nat Med."},{"key":"10.1016\/j.ctrv.2025.102993_b0445","doi-asserted-by":"crossref","first-page":"19794","DOI":"10.1038\/s41598-024-70779-8","article-title":"PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab","volume":"14","author":"Matsuki","year":"2024","journal-title":"Sci Rep."},{"key":"10.1016\/j.ctrv.2025.102993_b0450","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","article-title":"Pembrolizumab for the treatment of advanced salivary gland carcinoma: Findings of the Phase 1b KEYNOTE-028 Study","volume":"41","author":"Cohen","year":"2018","journal-title":"Am J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0455","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","article-title":"A Phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer","volume":"26","author":"Rodriguez","year":"2020","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ctrv.2025.102993_b0460","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2022.05.007","article-title":"Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study","volume":"171","author":"Even","year":"2022","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.ctrv.2025.102993_b0465","article-title":"NISCAHN: A phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08)","volume":"2","author":"Fayette","year":"2023","journal-title":"BMJ Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0470","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1534343","article-title":"Response efficacy of PD-1 and PD-L1 inhibitors in salivary gland cancers: a systematic review and meta-analysis","volume":"15","author":"Babamohamadi","year":"2025","journal-title":"Front Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2025.107280","article-title":"The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy","volume":"165","author":"Kano","year":"2025","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0480","article-title":"Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies","volume":"39(15_suppl):6079","author":"Bando","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101906","article-title":"Advances and challenges in precision medicine in salivary gland cancer","volume":"80","author":"Lassche","year":"2019","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ctrv.2025.102993_b0490","article-title":"The role of the EZH2 and H3K27me3 expression as a predictor of clinical outcomes in salivary duct carcinoma patients: A large-series study with emphasis on the relevance to the combined androgen blockade and HER2-targeted therapy","volume":"11","author":"Saigusa","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.ctrv.2025.102993_b0495","doi-asserted-by":"crossref","first-page":"59023","DOI":"10.18632\/oncotarget.19812","article-title":"Biomarker immunoprofile in salivary duct carcinomas: Clinicopathological and prognostic implications with evaluation of the revised classification","volume":"8","author":"Takase","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.ctrv.2025.102993_b0500","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1002\/cam4.2602","article-title":"Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling","volume":"8","author":"Gargano","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.ctrv.2025.102993_b0505","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1158\/1078-0432.CCR-19-3758","article-title":"The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype","volume":"26","author":"Linxweiler","year":"2020","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ctrv.2025.102993_b0510","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.anndiagpath.2019.04.001","article-title":"PD-L1 expression by immunohistochemistry in salivary duct carcinoma","volume":"40","author":"Hamza","year":"2019","journal-title":"Ann Diagn Pathol."},{"key":"10.1016\/j.ctrv.2025.102993_b0515","doi-asserted-by":"crossref","unstructured":"Ichimiya S, Fujimura A, Masuda M, Masuda S, Yasumatsu R, Umebayashi M, et al. Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma. Immunol Investig. Published online September 5, 2021. 2022;51:1\u201317. doi: 10.1080\/08820139.2021.1973491.","DOI":"10.1080\/08820139.2021.1973491"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722500115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722500115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:22:02Z","timestamp":1777555322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722500115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":103,"alternative-id":["S030573722500115X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102993","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Palliative systemic therapy for locally advanced or metastatic salivary duct carcinoma: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102993"}}